AHEAD 3–45 uses both early accelerating (plasma and CSF Aβ, Aβ PET) and late accelerating (tau PET) biomarkers to evaluate whether lecanemab can slow the accumulation of tau and prevent the cognitive decline associated with preclinical AD (21). The gene discussed is MAPT; the disease is Mental deterioration.